A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors

Clinical trial NCT01562899 · TERMINATED

Trial details

NCT number: NCT01562899
Sponsor: Pfizer
Status: TERMINATED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Metastatic Pancreatic Adenocarcinoma BRAF Mutated Melanoma

Start date: 2012-08-27
Primary completion: 2015-04-01
Enrollment: 77

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.